Refreshing the mesothelioma catalogue: tailoring cellular therapy in the DENIM trial
Mené sur 176 patients atteints d'un mésothéliome pleural non résécable (âge moyen : 68 ans), cet essai multicentrique de phase II/III évalue l'efficacité, du point de vue de la survie globale, et la toxicité de l'ajout, aux "meilleurs soins de support", de cellules dendritiques chargées de lysat de cellules tumorales allogéniques en traitement d'entretien
The two decades since the approval of cisplatin and pemetrexed for pleural mesothelioma 1 have seen little progress in development of new and more efficacious therapies. Recently, ipilimumab plus nivolumab has emerged as a treatment strategy conferring improved overall and progression-free survival relative to chemotherapy in this patient population, especially for those with non-epithelioid histology. 2 Although a meaningful subset of patients with pleural mesothelioma will have deep and sustained responses with immune checkpoint inhibitors, 3 primary resistance and transient disease control are common, highlighting the need for alteration of the treatment catalogue.
The Lancet Oncology 2023